Stockreport

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluron...

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF RAHWAY, N.J., January 07, 2026 BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007 [Read more]